INKON Life Technology Co Ltd
SZSE:300143
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.75
10.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
INKON Life Technology Co Ltd
INKON Life Technology Co Ltd
Total Receivables
INKON Life Technology Co Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
INKON Life Technology Co Ltd
SZSE:300143
|
Total Receivables
¥243.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
28%
|
|
|
H
|
Hygeia Healthcare Holdings Co Ltd
HKEX:6078
|
Total Receivables
¥660.6m
|
CAGR 3-Years
33%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
A
|
Aier Eye Hospital Group Co Ltd
SZSE:300015
|
Total Receivables
¥2.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
28%
|
|
|
X
|
XiAn International Medical Investment Co Ltd
SZSE:000516
|
Total Receivables
¥750.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
42%
|
CAGR 10-Years
33%
|
|
|
H
|
Huaxia Eye Hospital Group Co Ltd
SZSE:301267
|
Total Receivables
¥378.2m
|
CAGR 3-Years
28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sanbo Hospital Management Group Ltd
SZSE:301293
|
Total Receivables
¥115.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
INKON Life Technology Co Ltd
Glance View
INKON Life Technology Co., Ltd. engages in the research, development, production and sale of edible fungus. The company is headquartered in Qingdao, Shandong and currently employs 1,791 full-time employees. The company went IPO on 2011-04-22. Its medical services focus on cancer prevention, diagnosis, treatment and rehabilitation. The firm is also engaged in the research and development, manufacture and sales of medical equipment, as well as medical software development. Its medical equipment mainly include MASEP digital radiotherapy equipment, MASEP Gamma Knife and other large medical equipment. The firm distributes its products within domestic market and to overseas markets.
See Also
What is INKON Life Technology Co Ltd's Total Receivables?
Total Receivables
243.9m
CNY
Based on the financial report for Sep 30, 2024, INKON Life Technology Co Ltd's Total Receivables amounts to 243.9m CNY.
What is INKON Life Technology Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
28%
Over the last year, the Total Receivables growth was -2%. The average annual Total Receivables growth rates for INKON Life Technology Co Ltd have been -8% over the past three years , 9% over the past five years , and 28% over the past ten years .
You don't have any saved screeners yet
